Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03011333 · ClinicalTrials.gov registry record · Phase 2
Phase 2B Upper Extremity Nerve Block Study
A Phase 2 study, sponsored by Heron Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
NCT03011333 is a Phase 2 study that has completed, run by Heron Therapeutics. The registered enrollment target is 243 participants.
The verdict
NCT03011333, a Phase 2 study, has completed, sponsored by Heron Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
Study Summary
This is a Phase 2B, randomized, assessor-blind, active- and saline placebo-controlled, multicenter study in subjects undergoing augmentation mammoplasty to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX-011 when administered via ultrasound-guided lateral and medial pectoral nerve block before surgery.
Interventions
- DRUG Saline Placebo
- DRUG HTX-011
- DRUG Bupivacaine HCl without epinephrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2017-01-14 |
| Est. Completion | 2018-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03011333
The ClinicalTrials.gov registry entry for NCT03011333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heron Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Saline Placebo is the first listed.
NCT03011333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03011333 about?
NCT03011333 is a clinical study titled "Phase 2B Upper Extremity Nerve Block Study". This is a Phase 2B, randomized, assessor-blind, active- and saline placebo-controlled, multicenter study in subjects undergoing augmentation mammoplasty to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX-011 when administered via ultrasound-guided lateral and medial pectora...
What is the current status of trial NCT03011333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2017-01-14. Estimated completion is 2018-03-19.
What interventions are being tested in trial NCT03011333?
The interventions under investigation include: Saline Placebo (DRUG), HTX-011 (DRUG), Bupivacaine HCl without epinephrine (DRUG).
Who is sponsoring clinical trial NCT03011333?
This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.